Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

AmbioPharm

Tracked across 2 events · 13 articles · First seen May 27, 2026 · Last active Sep 17, 2026

Sentiment
30
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 60
Business
Impact: AmbioPharm is being acquired by CordenPharma, which will integrate its peptide manufacturing capabilities and facilities into CordenPharma's global network, allowing its shareholders to reinvest in the combined business.
May 27, 2026 · 7 articles
1 0
Business
CordenPharma, a global pharmaceutical contract development and manufacturing organization (CDMO) backed by private equity firm Astorg, announced the appointment of Dr. Jean-Luc Herbeaux as Chief Executive Officer effective 1 October 2026. Herbeaux succeeds Dr. Michael…
Impact: AmbioPharm is referenced as the peptide CDMO recently acquired by CordenPharma, cited as evidence of the company's expansion under the outgoing CEO. It plays no active role in the leadership change itself.
Sep 15, 2026 · 6 articles
ERGEN INTELLIGENCE
Track AmbioPharm live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.